Journal of clinical medicine research最新文献

{"title":"Survival After Partial Cystectomy Versus Radical Cystectomy for Non-Urothelial Carcinoma of the Bladder: A Population-Based Study.","authors":"Shuang Liu, Tai Song Wang, Ren Bin Yuan","doi":"10.14740/jocmr6263","DOIUrl":"10.14740/jocmr6263","url":null,"abstract":"<p><strong>Background: </strong>The aim of this study was to compare cancer-specific survival (CSS) and overall survival (OS) after partial cystectomy (PC) versus radical cystectomy (RC) in patients with stage T2N0M0 non-urothelial carcinoma of the bladder (NUCB).</p><p><strong>Methods: </strong>Data on patients with stage T2N0M0 NUCB treated with PC or RC were retrospectively retrieved from the Surveillance, Epidemiology, and End Results (SEER) database from 2007 to 2015. Propensity score matching (PSM) was used to create matched cohorts, which were used to calculate OS and CSS.</p><p><strong>Results: </strong>Among 999 histologically confirmed NUCB patients (752 in PC group and 247 in RC group), significant differences were found in age, marital status, tumor-related features, and treatment modalities. After 1:1 PSM, 169 pairs were obtained. In the matched cohort, the RC group had significantly higher 1-year, 3-year, and 5-year OS and CSS rates than the PC group (OS: P = 0.002; CSS: P = 0.004). Cox regression analysis showed that older age, unmarried status, and PC were independent risk factors for poor prognosis, while RC was associated with improved survival (OS: hazard ratio (HR) = 0.34, 95% confidence interval (CI): 0.26 - 0.44, P < 0.001; CSS: HR = 0.47, 95% CI: 0.31 - 0.72, P < 0.001). T2b-stage patients had lower cancer-specific mortality than T2a-stage patients (P = 0.01). Subgroup analysis indicated that RC generally led to better survival, except in the neuroendocrine carcinoma subgroup for OS (P = 0.085) and the other carcinoma subgroup for CSS (P = 0.132).</p><p><strong>Conclusions: </strong>This study reveals that RC is associated with superior CSS and OS compared to PC in patients with NUCB. Patient-related factors (age and marital status) and histological subtype significantly influence prognosis, highlighting the need for personalized treatment strategies.</p>","PeriodicalId":94329,"journal":{"name":"Journal of clinical medicine research","volume":"17 6","pages":"334-343"},"PeriodicalIF":1.6,"publicationDate":"2025-06-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12239827/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144610863","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of Chronic Obstructive Pulmonary Disease Burden on Patients With Atrial Fibrillation: A Nationwide Study.","authors":"Sherif Eltawansy, Faizan Ahmed, Grishma Sharma, Pawel Lajczak, Ogechukwu Obi, Hardik A Valand, Bhavin Patel, Dawood Shehzad, Mohamed Abugrin, Anam Mubasher, Asjad Salman, Joseph Heaton, Jesus Almendral","doi":"10.14740/jocmr6243","DOIUrl":"10.14740/jocmr6243","url":null,"abstract":"<p><strong>Background: </strong>Chronic obstructive pulmonary disease (COPD) and atrial fibrillation (Afib) are frequently comorbid, with COPD patients exhibiting a higher risk of Afib-related hospitalizations. This study investigated the relationship between COPD and Afib, focusing on 30-day readmission rates and outcomes.</p><p><strong>Methods: </strong>We conducted a retrospective cohort study using the Nationwide Readmissions Database (NRD) from 2016 to 2020. We included adult patients (≥ 18 years) with a primary diagnosis of Afib while excluding those with December discharges to ensure a complete 30-day follow-up. We compared patients with and without COPD, analyzing 30-day readmission rates, length of stay (LOS), hospital costs, in-hospital mortality, and associated factors using multivariable Cox and logistic regression models.</p><p><strong>Results: </strong>A total of 1,064,982 patients admitted with Afib were included, of which 873,070 had no COPD, and 191,912 had it. COPD patients were older (73.19 vs. 70.82 years), had a shorter LOS (coefficient = -0.05, P = 0.002, 95% confidence interval (CI): -0.08 to -0.02), and had a higher comorbidity burden (Elixhauser comorbidity index: 5.13 vs. 3.43, P < 0.0001). The 30-day readmission rate was significantly higher in the COPD group (16.0% vs. 9.0%, P < 0.001). Logistic regression revealed that COPD increased the odds of readmission (odds ratio: 1.35, 95% CI: 1.32 to 1.39, P < 0.001).</p><p><strong>Conclusion: </strong>COPD is a significant risk factor for 30-day readmission and in-hospital mortality among Afib patients, underscoring the need for integrated approaches targeting both diseases.</p>","PeriodicalId":94329,"journal":{"name":"Journal of clinical medicine research","volume":"17 6","pages":"309-319"},"PeriodicalIF":1.6,"publicationDate":"2025-06-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12239842/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144610860","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical Features of Migraine, Vestibular Migraine, and Tension-Type Headache and Their Vestibular Evoked Myogenic Potential Study.","authors":"Ai Juan Zhang, Li Qun Yu, Ai Yuan Zhang, Xian Zhu Cong, Li Zhou, Yang Liu","doi":"10.14740/jocmr6185","DOIUrl":"10.14740/jocmr6185","url":null,"abstract":"<p><strong>Background: </strong>Migraine, vestibular migraine (VM), and tension-type headache (TTH) are commonly associated with dizziness, vertigo, and postural instability, which increases patients' risk of falling and contributes to anxiety and depression. However, the vestibular pathophysiology underlying these primary headache disorders remains unclear. This study aimed to assess the saccular and utricular functions using vestibular evoked myogenic potentials (VEMPs), to investigate the peripheral and central vestibular involvement across these headaches.</p><p><strong>Methods: </strong>A total of 353 patients diagnosed with migraine, VM, or TTH, based on the International Classification of Headache Disorders, third edition (beta version, ICHD-3β), were recruited from the Dizziness and Headache Clinic at People's Hospital of Weifang between December 2019 and September 2022. All participants underwent standardized clinical assessments and demographic data collection. VEMP tests were performed using 95 dB air-conducted sound stimuli to evaluate peripheral and central vestibular functions prior to enrollment.</p><p><strong>Results: </strong>Sleep disturbances and psychiatric comorbidities (i.e., anxiety and depression) were significantly more prevalent in TTH patients compared to those with VM and migraine. VM patients also demonstrated higher rates of psychiatric comorbidities than migraine patients. The average headache duration in VM patients was 7.14 years, which was notably longer than the average dizziness duration of 4.03 years. Transient vertigo was reported in 22% of VM patients and 17.65% of TTH patients. The prevalence of occipital and/or neck pain was significantly higher in VM patients than in migraine patients. Absent ocular VEMP (oVEMP) responses, both unilateral and bilateral, were found at a significantly higher rate in VM patients compared to migraine patients. Additionally, cervical VEMP (cVEMP) asymmetry ratios (ARs) were significantly higher in VM patients compared to TTH patients, and marginally higher than in migraine patients (P = 0.05). Prolonged cVEMP latencies (right p13, n23, and interpeak intervals) were observed in both VM and migraine compared to TTH. Left-sided latencies were significantly prolonged in migraine than TTH.</p><p><strong>Conclusions: </strong>Psychiatric comorbidities were most pronounced in TTH, followed by VM and migraine. Both VM and TTH were associated with transient vertigo, exposing patients to drop-attack risk. The significantly higher occipital and/or neck pain reported in VM than in migraine may suggest the cervical neurovascular involvement in its pathophysiology. VEMP results indicate peripheral vestibular dysfunctions in VM patients and lower brainstem involvement in both VM and migraine patients, with the right-sided abnormalities more severe than the left-sided ones.</p>","PeriodicalId":94329,"journal":{"name":"Journal of clinical medicine research","volume":"17 6","pages":"344-355"},"PeriodicalIF":1.6,"publicationDate":"2025-06-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12239836/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144610859","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Oral Gonadotropin-Releasing Hormone Antagonists in the Treatment of Endometriosis: Advances in Research.","authors":"Jing Yi Wang, Yan Zhang, Jin Ding","doi":"10.14740/jocmr6236","DOIUrl":"10.14740/jocmr6236","url":null,"abstract":"<p><p>Non-peptide gonadotropin-releasing hormone (GnRH) receptor antagonists exhibit remarkable potency and specificity in inhibiting GnRH receptor activity. The orally administered versions of these drugs, notably elagolix and relugolix, have obtained official clearance in various countries for treating moderate-to-severe endometriosis-related pain. Concurrently, linzagolix and opigolix (ASP1707) continue to advance through late-stage clinical trials. The primary objective of this review is to comprehensively evaluate the clinical efficacy and safety profile of oral GnRH antagonists, specifically elagolix, relugolix, linzagolix, and opigolix, for the management of endometriosis-associated pain. Specifically, this study summarizes and analyzes their effectiveness in alleviating dysmenorrhea and non-menstrual pelvic pain, evaluates the dose-dependent impacts on bone mineral density and adverse effects such as hot flushes, and explores the role of add-back therapy in improving treatment safety and patient adherence. Research has demonstrated that oral GnRH antagonists effectively alleviate endometriosis-related pain while enhancing patients' quality of life. Furthermore, when combined with add-back therapy, these medications enhance treatment safety and contribute to greater patient compliance. Compared to alternative hormonal treatments, oral GnRH antagonists emerge as a particularly promising approach for managing endometriosis.</p>","PeriodicalId":94329,"journal":{"name":"Journal of clinical medicine research","volume":"17 6","pages":"299-308"},"PeriodicalIF":1.6,"publicationDate":"2025-06-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12239828/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144610861","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Retraction Statement.","authors":"","doi":"10.14740/jocmr6299","DOIUrl":"10.14740/jocmr6299","url":null,"abstract":"<p><p>[This retracts the article DOI: 10.14740/jocmr2541e.][This retracts the article DOI: 10.14740/jocmr3470w.][This retracts the article DOI: 10.14740/jocmr2443w.].</p>","PeriodicalId":94329,"journal":{"name":"Journal of clinical medicine research","volume":"17 6","pages":"356"},"PeriodicalIF":1.6,"publicationDate":"2025-06-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12239837/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144610862","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Long-Term Effects of the Selective Inhibitor of Urate Transporter 1, Dotinurad, on Metabolic Parameters and Renal Function in Japanese Patients With Asymptomatic Hyperuricemia.","authors":"Hidekatsu Yanai, Hiroki Adachi, Mariko Hakoshima, Hisayuki Katsuyama","doi":"10.14740/jocmr6250","DOIUrl":"10.14740/jocmr6250","url":null,"abstract":"<p><strong>Background: </strong>Epidemiological studies have reported that hyperuricemia is associated with the development of metabolic syndrome, hypertension, dyslipidemia, type 2 diabetes, and chronic kidney disease (CKD). Renal uric acid (UA) reabsorption is mainly mediated by urate transporter 1 (URAT1) in renal proximal tubule epithelial cells. Recently, URAT1 was found to be expressed in the liver and adipose tissue in addition to the kidney. UA enters such organs via URAT1 and induces inflammation and oxidative stress, which may lead to metabolic disorders. We investigated the effects of long-term treatment with the novel uricosuric drug, a highly selective inhibitor of URAT1, dotinurad, on metabolic parameters and renal function.</p><p><strong>Methods: </strong>We retrospectively picked up patients who had taken dotinurad for the treatment of asymptomatic hyperuricemia for more than 2 years. We compared metabolic parameters and renal function at baseline with the data at 6, 12, 18, and 24 months after starting dotinurad.</p><p><strong>Results: </strong>Pharmacologically, dotinurad decreases serum UA, by selectively inhibiting URAT1 and decreasing renal reabsorption of UA, which was supported by our result that dotinurad significantly increased urine UA and reduced serum UA. In addition to UA-lowering, dotinurad was associated with improvements in body weight, liver function, hepatic steatosis index as the marker for metabolic dysfunction-associated steatotic liver disease (MASLD), serum lipids, and albuminuria. The ATP-binding cassette transporter G2 (ABCG2) regulates renal and intestinal excretion of UA and uremic toxins and strongly affects renal function. Our study also indicates that switching from xanthine oxidase inhibitors, which inhibit ABCG2, to dotinurad, which does not inhibit ABCG2, was beneficial for albuminuria and maintaining the estimated glomerular filtration rate.</p><p><strong>Conclusion: </strong>Dotinurad may improve obesity, MASLD, serum lipids, and CKD by blocking the entry of UA via URAT1 to the adipose tissue, liver, and kidney.</p>","PeriodicalId":94329,"journal":{"name":"Journal of clinical medicine research","volume":"17 6","pages":"320-333"},"PeriodicalIF":1.6,"publicationDate":"2025-06-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12239830/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144610864","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Anti-Breast Cancer Effects of Thymoquinone-Chemotherapeutic Combinations: A Systematic Review of the Latest <i>In Vitro</i> and <i>In Vivo</i> Studies.","authors":"Nur Qodir, Legiran, Zen Hafy, Didit Pramuditho, Muhammad Baharul Iman, Fara Syafira, Raehan Satya Deanasa, Putri Mahirah Afladhanti","doi":"10.14740/jocmr6230","DOIUrl":"10.14740/jocmr6230","url":null,"abstract":"<p><strong>Background: </strong>Breast cancer is a leading malignancy among women globally, with chemotherapy as a cornerstone of treatment. However, the side effects and toxicity associated with chemotherapy necessitate the exploration of adjunctive therapies to improve efficacy and reduce adverse effects. Thymoquinone (TQ) has shown potential anti-cancer properties. This systematic review aimed to evaluate the effectiveness of TQ in combination with chemotherapeutic agents in treating breast cancer.</p><p><strong>Methods: </strong>This study thoroughly reviewed and synthesized existing research following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 2020 guidelines. The selected databases, including PubMed, ProQuest, ScienceDirect, Epistemonikos, and Google Scholar, were searched over the past 10 years. Eligibility criteria were based on the PICOS framework, focusing on experimental studies involving TQ-chemotherapy combinations. Data extraction and quality assessment were performed using SYRCLE and SCIRAP tools. This review included 18 <i>in vitro</i> and six <i>in vivo</i> studies.</p><p><strong>Results: </strong>Findings revealed that TQ enhances the efficacy of chemotherapeutic agents by inducing apoptosis, enhancing autophagy, inhibiting tumor growth, and regulating cancer cell signaling pathways as well as multiple phases of the cell cycle. Additionally, TQ reduced chemotherapy-related toxicity, such as heart, blood, liver, and kidney damage, and also improved patient tolerance. Nanoparticle-based delivery systems further amplified these synergistic effects.</p><p><strong>Conclusions: </strong>The TQ-chemotherapy combination shows significant potential as a therapy for breast cancer, enhancing treatment efficacy while mitigating side effects. Future clinical studies are needed to establish its safety and therapeutic applicability.</p>","PeriodicalId":94329,"journal":{"name":"Journal of clinical medicine research","volume":"17 5","pages":"270-284"},"PeriodicalIF":1.6,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12151103/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144277273","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correction to: Left Ventricular Non-Compaction, Atrial Fibrillation and <i>ANK2</i> Mutation in a Young Athlete.","authors":"Gabriele De Masi De Luca, Francesco Brancati, Luigi Sciarra, Arianna Di Daniele, Zefferino Palama, Antonio Gianluca Robles, Antonio Scara, Alessio Borrelli, Martina Nesti, Paola Papadia, Giuseppe Prete, Giuseppe De Masi De Luca, Silvio Romano","doi":"10.14740/jocmr6126c1","DOIUrl":"10.14740/jocmr6126c1","url":null,"abstract":"<p><p>[This corrects the article DOI: 10.14740/jocmr6126.].</p>","PeriodicalId":94329,"journal":{"name":"Journal of clinical medicine research","volume":"17 5","pages":"297"},"PeriodicalIF":1.6,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12151092/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144277275","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Kinesiophobia in Systemic Sclerosis: Relationship With Functional Status, Pulmonary Fibrosis, Depression, and Other Clinical Parameters.","authors":"Canan Balamir Pehlivan, Mustafa Akif Sariyildiz, Remzi Cevik, Serkan Erbatur, Ibrahim Batmaz","doi":"10.14740/jocmr6202","DOIUrl":"10.14740/jocmr6202","url":null,"abstract":"<p><strong>Background: </strong>The aim of this study was to evaluate the levels of kinesiophobia and its relationship with functional status, quality of life, pulmonary involvement, depression, and other clinical parameters of the disease in patients with systemic sclerosis (SSc).</p><p><strong>Methods: </strong>A total of 100 individuals (40 patients with SSc and 60 healthy controls) were included in the study. The Tampa scale was used to assess kinesiophobia. Beck Depression Inventory (BDI) was used to assess depression. Scleroderma Health Assessment Questionnaire (SSc-HAQ) was used to assess functional status. Modified Rodnan skin score was used to assess skin thickness, and high-resolution computed tomography was used to assess lung fibrosis.</p><p><strong>Results: </strong>The mean Tampa kinesiophobia score was significantly higher in patients with SSc compared to healthy controls. Depressive symptoms were present in 57.5% of patients with SSc. Disease duration, pain, fatigue, disease activity, functional status, pulmonary fibrosis, and depressive symptoms were correlated with kinesiophobia in patients with SSc.</p><p><strong>Conclusion: </strong>There is an increased prevalence of kinesiophobia in patients with SSc, which seems to be more closely associated with disease duration, pain levels, and depressive symptoms.</p>","PeriodicalId":94329,"journal":{"name":"Journal of clinical medicine research","volume":"17 5","pages":"256-261"},"PeriodicalIF":1.6,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12151129/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144277277","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Does Receiving Information on Clinical Trials Affect Patients' Condition?","authors":"Hideaki Shimada, Keisuke Okamura, Tetsuji Ohyama, Hidenori Urata, Osamu Imakyure","doi":"10.14740/jocmr6252","DOIUrl":"10.14740/jocmr6252","url":null,"abstract":"<p><strong>Background: </strong>When performing clinical trials on lifestyle-related diseases at our hospital, we have sometimes experienced patients who fulfilled the inclusion criteria at the time of receiving an explanation of the trial but who no longer met the criteria when they arrived to provide their consent to participate 1 month later. In some of these cases, we noticed that the patient's lifestyle subsequently improved. Therefore, we hypothesized that receiving information on clinical trials may affect lifestyle-related diseases.</p><p><strong>Methods: </strong>We enrolled patients aged 85 years or younger who received information on a double-blind randomized clinical trial on treatment-resistant hypertension (R-HT) or one on diabetic nephropathy. In these patients, we evaluated whether the trial information affected a range of variables. In addition, we compared the rate of change in variables between two groups, i.e., patients who became ineligible to participate and were not randomized (early dropouts) and patients who decided to participate and were randomized (patients randomized to treatment). We also conducted a questionnaire on changes in patients' motivation level, health awareness and behavior, and expectations and concerns and evaluated changes from before to after receiving an explanation of the trial.</p><p><strong>Results: </strong>Seven patients who received an explanation of the R-HT trial and 14 who received an explanation of the diabetic nephropathy trial participated in the present study. The only significant change in any variable was in the R-HT clinical trial, where systolic and diastolic blood pressure significantly decreased in the early dropout group. There were no significant differences between the two groups in the rate of change in variables. After receiving information about one of the studies, patients who became more proactive or involved in changing their health-related behavior, such as their exercise, eating, and drinking habits, increased in both groups.</p><p><strong>Conclusions: </strong>Receiving information on a clinical trial on hypertension can significantly affect blood pressure. Future research should examine whether providing information on clinical trials on other lifestyle-related diseases motivates patients to improve their lifestyles.</p>","PeriodicalId":94329,"journal":{"name":"Journal of clinical medicine research","volume":"17 5","pages":"247-255"},"PeriodicalIF":1.6,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12151097/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144277276","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}